Trulicity Injection, Solution
Product Images NDC 50090-6456

Product Visual Gallery

This gallery contains 48 technical images submitted to the FDA as part of the official labeling for Trulicity (NDC 50090-6456). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500906456)

TRULICITY (Dulaglutide) Injection, 1.5 mg/0.5 mL, single-dose pens packaged as 4 pens per box. The label from A-S Medication Solutions includes storage instructions to refrigerate at 36 to 46 °F and a caution that the product must be protected from light and not frozen. The product is indicated for once-weekly use and notes disposal after use.*

FDA Label Image

Logo (Logo)

FDA Label Image

Qr Code (Qr V1)

FDA Label Image

Figure (Trulicity Ifu 0point75 Injection Sites Back V1)

An anatomical illustration showing the recommended subcutaneous injection sites for TRULICITY (Dulaglutide) injection. The highlighted areas on the upper outer arms indicate preferred locations for administering the injection.*

FDA Label Image

Figure (Trulicity Ifu 0point75 Injection Sites Front V1)

An illustration showing a human figure with highlighted yellow areas on the abdomen and upper thighs, indicating common injection sites for subcutaneous administration of medication.*

FDA Label Image

Figure (Trulicity Ifu 1point5 Injection Sites Back V1)

An instructional diagram showing a human figure from the back with blue highlighted areas on the upper outer arms, indicating recommended injection sites for subcutaneous administration.*

FDA Label Image

Figure (Trulicity Ifu 1point5 Injection Sites Front V1)

An instructional illustration showing the body areas suitable for subcutaneous injection of TRULICITY (Dulaglutide). Highlighted injection sites include the abdomen around the navel and the front of both thighs. The image depicts these areas in blue on a simplified human figure.*

FDA Label Image

Figure (Trulicity Ifu 3mg Injection Sites V1)

Illustration showing recommended subcutaneous injection sites on the human body. Dark shaded areas indicate injection locations on the abdomen, thighs, and upper arms, viewed from both front and back.*

FDA Label Image

Figure (Trulicity Ifu 4point5mg Injection Sites V1)

An instructional illustration showing recommended subcutaneous injection sites on the human body. Highlighted areas include the abdomen, outer upper arms, and front and outer thighs, viewed from both front and back perspectives.*

FDA Label Image

Figure (Trulicity Ifu Check V1)

FDA Label Image

Exclamation (Trulicity Ifu Exclamation V1)

TRULICITY 1.5 mg/0.5 mL injection solution in a single-dose pen for subcutaneous use, labeled by A-S Medication Solutions. The image shows a small, light blue pen injector without visible text other than the product colors and shape.*

FDA Label Image

Figure (Trulicity Ifu Expiration Location V2)

An instructional diagram showing the location of the expiration date on a TRULICITY injection pen. The image highlights the expiration date area with a red arrow pointing to a black label on the pen, indicating where to find the expiration information on the subcutaneous injection device.*

FDA Label Image

Figure (Trulicity Ifu Inspect V1)

FDA Label Image

Locked (Trulicity Ifu Locked V1)

TRULICITY 1.5 mg/0.5 mL injection solution in a subcutaneous pen injector. The label shows the proprietary name TRULICITY, active ingredient Dulaglutide, strength, dosage form, and the labeler A-S Medication Solutions. The pen injector is mostly white with purple and gray accents and includes a dose window and injection button.*

FDA Label Image

Figure (Trulicity Ifu Prepare V1)

FDA Label Image

Figure (Trulicity Ifu Remove V1)

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 F2 V3)

Illustration showing hands preparing a TRULICITY (dulaglutide) injection device. One hand holds the pen-like injector, while the other hand removes or attaches a black cap from the device, indicated by a downward arrow. This instructional image demonstrates part of the injection preparation process for subcutaneous use.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 F3 V3)

An instructional illustration showing a person holding a prefilled injection pen device for subcutaneous use, pulling a purple safety or activation tab, likely demonstrating preparation steps for administering a dose of an injectable medication.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 F4 V3)

An instructional diagram showing a person preparing a subcutaneous injection with a pen device. The image includes a close-up inset demonstrating the needle or device tip, and a time indicator suggesting a 5-10 second duration for holding the injection in place. The illustration is consistent with preparation or administration steps for an injectable medication such as TRULICITY (Dulaglutide).*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 F5 V3)

An instructional illustration showing a hand holding a prefilled injection pen with a safety cap being disposed into a biohazard sharps container. The image emphasizes safe disposal of used injection equipment.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 Pen Parts V3)

An instructional diagram of a TRULICITY (Dulaglutide) injection pen showing labeled parts including the injection button at the top, lock ring, indicator, lock/unlock symbols, medicine reservoir, clear base, and base cap at the bottom where the needle is located. The diagram clarifies the orientation with 'Top' and 'Bottom/Needle End' noted.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 Pen V3)

TRULICITY 1.5 mg/0.5 mL injection, solution in a single-dose prefilled pen for subcutaneous use. The pen features a white body with a purple and yellow label, green cap, and a transparent needle shield. Labeler is A-S Medication Solutions, NDC 50090-6456.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 F2 V3)

An instructional illustration showing the proper way to hold and connect parts of a TRULICITY injection pen device. It depicts one hand holding the pen upright while the other hand attaches or removes a component from the bottom, with directional arrows indicating movement.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 F3 V3)

An instructional illustration showing a person administering a subcutaneous injection in the abdomen area using an injection device. The image highlights the hand positioning and the angle of injection, with a purple arrow indicating the twisting or pressing action needed to activate the device.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 F4 V3)

An instructional illustration showing the proper subcutaneous injection technique for TRULICITY (dulaglutide) injection, solution 1.5 mg/0.5 mL. The image includes a close-up inset highlighting the syringe contents and recommends holding the injection site for 5-10 seconds after administration.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 F5 V3)

Illustration showing a hand holding a syringe over a biohazard sharps disposal container, demonstrating safe injection needle disposal.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 Pen Parts V3)

An illustration of a TRULICITY (Dulaglutide) injection pen showing labeled parts including the injection button, lock ring, indicator, lock/unlock icons, medicine chamber, clear base, and base cap. The diagram indicates orientation with the top near the injection button and the bottom at the needle end.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 Pen V3)

TRULICITY 1.5 mg/0.5 mL injection pen displays a single-dose, prefilled subcutaneous injection device with a white barrel and blue and green accent colors. The device features a clear cap on the needle end and a green injection button on the opposite end. The label includes minimal visible text and markings consistent with a prefilled injection pen by A-S Medication Solutions.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg F2 V1)

An instructional illustration showing a gloved hand holding a prefilled pen injector, facing downward, with another hand holding a cap or component below it. An arrow points downward, indicating the removal or attachment step. A red lock icon and red frame surround the image, suggesting a safety or locking mechanism.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg F3 V1)

Illustration showing a person preparing a subcutaneous injection using a prefilled syringe. One hand is holding the syringe while the other is twisting or removing a cap or protective cover.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg F4 V1)

An instructional illustration showing hands administering a subcutaneous injection using a pre-filled pen device. The image highlights the 5-10 second injection duration and indicates that the injection is complete when the gray plunger in the device is fully visible.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg F5 V1)

An illustration showing a hand holding a prefilled injection syringe above a biohazard sharps disposal container, demonstrating safe disposal of the injection device after use.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg Pen Parts V1)

An instructional diagram of the TRULICITY injection pen showing labeled parts including the Injection Button, Lock Ring, Indicator, Lock/Unlock switch, Medicine reservoir, Clear Base, and Base Cap. The diagram indicates orientation with Top and Bottom/Needle End markers.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg Pen V1)

TRULICITY 1.5 mg/0.5 mL subcutaneous injection solution in a prefilled pen injector, labeled for a single-use dose. The device features a white body with purple and green accents and a protective needle shield. Manufactured by A-S Medication Solutions.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 F2 V1)

An instructional illustration showing a hand holding a TRULICITY (dulaglutide) injection pen solution and another hand holding the pen cap. The diagram includes a downward arrow indicating removal or attachment of the cap from the injection pen prior to use.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 F3 V1)

An instructional illustration showing a person administering a subcutaneous injection using a prefilled pen device, with arrows indicating the twisting off of a green cap before the injection. The image depicts hand positioning and injection into the abdominal area.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 F4 V1)

An instructional illustration showing how to use the TRULICITY injection, solution, 1.5 mg/0.5 mL subcutaneous pen. It depicts hands holding the pen injecting into the abdomen, with a zoomed inset highlighting the gray plunger. The caption indicates that the injection is complete when the gray plunger is visible, recommending a 5-10 second hold time.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 F5 V1)

An instructional illustration showing a hand holding a prefilled syringe above a biohazard sharps disposal container, suggesting safe disposal of the used injection device.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 Pen Parts V1)

An instructional labeled diagram of a TRULICITY (Dulaglutide) injection pen showing its components. Labels identify the Injection Button, Lock Ring, Indicator, Lock/Unlock mechanism, Medicine reservoir, Clear Base, and Base Cap. Arrows indicate the pen's top and bottom/needle ends, illustrating key functional parts for subcutaneous use.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 Pen V1)

TRULICITY 1.5 mg/0.5 mL injection solution in a single-dose, prefilled subcutaneous injection pen. The pen has a white body with a purple and green label band and a transparent cap. Labeler is A-S Medication Solutions, with NDC 50090-6456.*

FDA Label Image

Figure (Trulicity Ifu Unfold V1)

An instructional fold-out sheet showing a zigzag fold pattern with arrows indicating to unfold and lay flat. Text below instructs to read both sides for full instructions, likely accompanying a medication package insert or patient information leaflet.*

FDA Label Image

Unlocked (Trulicity Ifu Unlock V1)

TRULICITY 1.5 mg/0.5 mL injection, solution, subcutaneous is shown in a prefilled pen device. The label on the pen includes the proprietary name TRULICITY and the active ingredient Dulaglutide. The label also contains dosing and administration information along with the manufacturer, A-S Medication Solutions. The pen shows markings for dose measurement and has a purple cap.*

FDA Label Image

Figure 1 (Trulicity Pi F1 V2)

A pharmacokinetic forest plot showing the ratio and 90% confidence intervals for area under the curve (AUC) and peak concentration (Cmax) of dulaglutide relative to reference values. The plot evaluates intrinsic factors such as weight, age, sex, race, and renal and hepatic impairment, with ratios displayed along a horizontal axis ranging from 0 to 2.*

FDA Label Image

Figure 2 (Trulicity Pi F2 V2)

A forest plot chart showing pharmacokinetic (PK) ratios and 90% confidence intervals (CI) for various coadministered drugs relative to a reference. The chart lists drugs such as Lisinopril, Metoprolol, Digoxin, Norelgestromin, Ethinylestradiol, Atorvastatin, Metformin, Acetaminophen, S-Warfarin, R-Warfarin, and Sitagliptin, with corresponding AUC and Cmax ratios plotted along the horizontal axis marked 0.0 to 2.0.*

FDA Label Image

Figure 3 (Trulicity Pi F3 V3)

A line graph showing the least squares mean HbA1c percentage over 52 weeks post-randomization comparing TRULICITY 1.5 mg, TRULICITY 0.75 mg, Sitagliptin 100 mg, and Placebo. The x-axis represents weeks, and the y-axis represents HbA1c percentage, illustrating the changes in HbA1c levels over time for each treatment group.*

FDA Label Image

Figure 4 (Trulicity Pi F4 V3)

A line graph depicting mean HbA1c percentage over weeks post-randomization for TRULICITY injection, solution subcutaneous at strengths 1.5 mg, 3 mg, and 4.5 mg. The x-axis shows weeks from baseline to week 36. The y-axis shows mean HbA1c (%) ranging approximately from 6.5 to 8.5. Lines represent decreasing HbA1c values over time for all three strengths.*

FDA Label Image

Figure 5 (Trulicity Pi F5 V2)

A line graph showing the least squares mean HbA1c (%) over 26 weeks post-randomization for TRULICITY 1.5 mg, TRULICITY 0.75 mg, Exenatide, and placebo groups. The graph illustrates changes at baseline, week 13, and week 26, indicating comparative trends in HbA1c reduction among these treatments.*

FDA Label Image

Figure 6 (Trulicity Pi F6 V2)

A Kaplan-Meier curve comparing the percentage of patients with an event over approximately 6 years between Dulaglutide and placebo groups. The y-axis shows patients with an event (%) and the x-axis shows time from randomization (years). Dulaglutide group shows a slightly lower event rate than placebo. Hazard ratio (HR) is 0.88 with a 95% confidence interval of 0.79 to 0.99.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.